Joffe Steven, Harrington David P, George Stephen L, Emanuel Ezekiel J, Budzinski Lindsay A, Weeks Jane C
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
BMJ. 2004 Jun 19;328(7454):1463. doi: 10.1136/bmj.38118.685289.55. Epub 2004 May 26.
To assess whether publicly funded adult cancer trials satisfy the uncertainty principle, which states that physicians should enroll a patient in a trial only if they are substantially uncertain which of the treatments in the trial is most appropriate for the patient. This principle is violated if trials systematically favour either the experimental or the standard treatment.
Retrospective cohort study of completed cancer trials, with randomisation as the unit of analysis.
Two cooperative research groups in the United States.
93 phase III randomised trials (103 randomisations) that completed recruitment of patients between 1981 and 1995.
Whether the randomisation favoured the experimental treatment, the standard treatment, or neither treatment; effect size (outcome of the experimental treatment compared with outcome of the standard treatment) for each randomisation.
Three randomisations (3%) favoured the standard treatment, 70 (68%) found no significant difference between treatments, and 30 (29%) favoured the experimental treatment. The average effect size was 1.20 (95% confidence interval 1.13 to 1.28), reflecting a slight advantage for the experimental treatment.
In cooperative group trials in adults with cancer, there is a measurable average improvement in disease control associated with assignment to the experimental rather than the standard arm. However, the heterogeneity of outcomes and the small magnitude of the advantage suggest that, as a group, these trials satisfy the uncertainty principle.
评估由公共资金资助的成人癌症试验是否符合不确定性原则,该原则指出,只有当医生对试验中的哪种治疗方法最适合患者存在很大不确定性时,才应将患者纳入试验。如果试验系统性地偏向实验性治疗或标准治疗,则违反了这一原则。
以随机分组为分析单位,对已完成的癌症试验进行回顾性队列研究。
美国的两个合作研究小组。
93项III期随机试验(103次随机分组),这些试验在1981年至1995年期间完成了患者招募。
随机分组是否偏向实验性治疗、标准治疗或两者均无偏向;每次随机分组的效应大小(实验性治疗结果与标准治疗结果的比较)。
三次随机分组(3%)偏向标准治疗,70次(68%)发现治疗之间无显著差异,30次(29%)偏向实验性治疗。平均效应大小为1.20(95%置信区间1.13至1.28),表明实验性治疗略有优势。
在成人癌症合作组试验中,与分配到标准治疗组相比,分配到实验性治疗组可使疾病控制得到可测量的平均改善。然而,结果的异质性和优势的微小程度表明,总体而言,这些试验符合不确定性原则。